We are committed to making a major contribution in efforts to eliminate malaria as a public health threat, particularly in our region.
One of the leading causes of mortality and morbidity globally, malaria was responsible for more than 627,000 deaths, and 241 million clinical cases in 2020 – an increase of 12% compared to the previous year, according the WHO’s latest World Malaria Report. An estimated 2.5 billion people are at risk of the disease, with young children and pregnant women most affected.
A two-way pipeline will be created where our research discoveries can be tested in the field, and field programs inform discovery research through our long-standing connections with vulnerable target populations, especially in Papua New Guinea and Myanmar.
Through this program, Burnet will contribute to:
reaching the WHO elimination targets of a 90 percent reduction in malaria incidence and mortality through an active program of basic, discovery and translational research and in-field education, prevention and treatment programs.
supporting country programs in our region that assist WHO in reaching targets of elimination in at least 35 countries by 2030.
The global burden of malaria has increased, alongside the spread of drug-resistant infections. There is now a sense of urgency to develop more effective vaccines to combat the disease and accelerate towards elimination.
This website was developed with the generous support of a donor.
Burnet Institute (Australia) is located on the traditional land of the Boon Wurrung people and we offer our respects to their Elders past and present. We recognise and respect the continuation of cultural, spiritual and educational practices of Aboriginal and Torres Strait Islander peoples of this land.
It looks like something may have gone wrong, and some of the resources required to load the page may not have loaded correctly.